President and CEO, PhRMA
Ubl has headed the Pharmaceutical Research and Manufacturers of America, the advocacy group for biopharmaceutical research companies, since 2015. In June, PhRMA sued the federal government, alleging that the Inflation Reduction Act’s provisions allowing Medicare to negotiate drug prices are unconstitutional. At the time, Ubl called the program bad policy and warned it could threaten research and development efforts. PhRMA this year under Ubl’s leadership also sought to refute allegations that drug manufacturers are behind high pharmaceutical prices. The association has promoted and commissioned research showing hospitals mark up medicines 500% and that PBMs drive up prices through fees, which have doubled in the past five years. Ubl previously led the Advanced Medical Technology Association for 16 years.